Nature Reviews Clinical Oncology, Published online: 18 November 2025; doi:10.1038/s41571-025-01106-xT-DXd plus pertuzumab effective as first-line therapy

Nature Reviews Clinical Oncology, Published online: 17 November 2025; doi:10.1038/s41571-025-01107-wSentinel lymph node biopsy improves surgical management of cervical cancer

Nature Reviews Clinical Oncology, Published online: 11 November 2025; doi:10.1038/s41571-025-01085-zThird-generation EGFR tyrosine kinase inhibitors such as osimertinib have substantially improved clinical outcomes in advanced-stage EGFR-mutant non-small-cell lung cancer, but resistance remains inevitable. In this Review, the authors discuss biomarker-directed and biomarker-unselected approaches to overcome established resistance to osimertinib, as well as pre-emptive upfront strategies to delay or prevent the occurrence of osimertinib resistance.

Nature Reviews Clinical Oncology, Published online: 11 November 2025; doi:10.1038/s41571-025-01084-0A better understanding of the development and progression of heterogeneity in oesophageal adenocarcinoma and its precursor condition, Barrett oesophagus, is crucial for improving surveillance and treatment strategies. The authors of this Review outline the current knowledge of the causes, mediators and therapeutic implications of spatial and temporal heterogeneity in these diseases.

Nature Reviews Clinical Oncology, Published online: 10 November 2025; doi:10.1038/s41571-025-01103-0T-DXd shows promise in neoadjuvant therapy for HER2+ breast cancer

Nature Reviews Clinical Oncology, Published online: 07 November 2025; doi:10.1038/s41571-025-01098-8Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters

Nature Reviews Clinical Oncology, Published online: 07 November 2025; doi:10.1038/s41571-025-01096-wReply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’

Nature Reviews Clinical Oncology, Published online: 04 November 2025; doi:10.1038/s41571-025-01101-2From the ESMO Congress 2025

Nature Reviews Clinical Oncology, Published online: 03 November 2025; doi:10.1038/s41571-025-01087-xDormant tumour cells that survive initial therapy can awaken years later to seed metastases. New data from a phase II trial indicate that intercepting this dormancy by targeting autophagy and mTOR signalling might prevent breast cancer relapse before it begins, opening a path towards proactive prevention disease recurrence.

Nature Reviews Clinical Oncology, Published online: 31 October 2025; doi:10.1038/s41571-025-01097-9Domvanalimab plus zimberelimab shows promise in upper-tract cancers

Nature Reviews Clinical Oncology, Published online: 31 October 2025; doi:10.1038/s41571-025-01091-1Perioperative therapy effective in high-risk HCC

Nature Reviews Clinical Oncology, Published online: 28 October 2025; doi:10.1038/s41571-025-01094-yIza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma

Nature Reviews Clinical Oncology, Published online: 27 October 2025; doi:10.1038/s41571-025-01092-0Belzutifan as a new option in pheochromocytomas and paragangliomas

Nature Reviews Clinical Oncology, Published online: 27 October 2025; doi:10.1038/s41571-025-01088-wIvonescimab delays disease progression

Nature Reviews Clinical Oncology, Published online: 27 October 2025; doi:10.1038/s41571-025-01090-2Sacituzumab tirumotecan improves OS in EGFR TKI-resistant NSCLC

Nature Reviews Clinical Oncology, Published online: 27 October 2025; doi:10.1038/s41571-025-01086-yCombination neoadjuvant chemotherapy improves outcomes

Nature Reviews Clinical Oncology, Published online: 27 October 2025; doi:10.1038/s41571-025-01089-9HER2-directed therapy improves urothelial cancer outcomes

Nature Reviews Clinical Oncology, Published online: 09 October 2025; doi:10.1038/s41571-025-01080-4Patients with unresectable stage III non-small-cell lung cancer without EGFR or ALK mutations typically receive the PACIFIC regimen — concurrent chemoradiotherapy (cCRT) followed by consolidation with durvalumab — whereas those with EGFR-mutant disease typically receive cCRT followed by an EGFR inhibitor. Nonetheless, a subset of patients within this heterogeneous group might be able to completely avoid consolidation therapy, whereas others are unable to tolerate cCRT. In this Review, the authors describe the standard-of-care approach in this setting, followed by discussions of treatment optimization for specific subgroups, as well as important future research questions.

Nature Reviews Clinical Oncology, Published online: 08 October 2025; doi:10.1038/s41571-025-01074-2Extracellular vesicles (EVs), a diverse range of membrane-delimited particles, have multiple cellular functions and, when released by cancer cells, can promote tumour growth and metastatic dissemination. The authors of this Review describe advances in the development of EVs as biomarkers and cancer therapeutics, focusing on clinical translation of EVs into diagnostic and therapeutic clinical tools.

Nature Reviews Clinical Oncology, Published online: 08 October 2025; doi:10.1038/s41571-025-01079-xEpstein–Barr virus (EBV) infection has a key aetiological role in endemic nasopharyngeal carcinoma (NPC). The authors of this Review discuss advances in NPC screening, which leverage the detection of either plasma EBV DNA or serum antibodies targeting EBV antigens, as well as in prevention, which relies on prophylactic and therapeutic vaccines for NPC.

Nature Reviews Clinical Oncology, Published online: 03 October 2025; doi:10.1038/s41571-025-01077-zPatients with advanced-stage pancreatic ductal adenocarcinoma often have dismal outcomes, despite an initial response sometimes to standard-of-care chemotherapy. This treatment refractoriness partly reflects the effects of the tumour microenvironment (TME), which is highly heterogeneous but can include a dense desmoplastic stroma as well as various immune cell and cancer-associated fibroblast populations, most of which collectively promote resistance to treatment and disease progression. In this Review, the authors summarize the role of the TME in determining the outcomes of patients with pancreatic ductal adenocarcinoma, and consider novel therapeutic approaches that might promote the development of a tumour-suppressive TME.

Nature Reviews Clinical Oncology, Published online: 03 October 2025; doi:10.1038/s41571-025-01083-1Author Correction: Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care

Nature Reviews Clinical Oncology, Published online: 02 October 2025; doi:10.1038/s41571-025-01075-1Chimeric antigen receptor (CAR) T cell therapy is revolutionizing the treatment of haematological malignancies, but expanding applicability to solid tumours presents substantial challenges. This Review describes key strategies to optimize CAR T cell therapy for solid tumours across areas spanning from target selection to response and safety evaluation.

Nature Reviews Clinical Oncology, Published online: 26 September 2025; doi:10.1038/s41571-025-01082-2ALASCCA: an aspirin a day keeps colorectal cancer away

Nature Reviews Clinical Oncology, Published online: 23 September 2025; doi:10.1038/s41571-025-01081-3MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib